Fortis Therapeutics, a UCSF Founded Startup, Closes $40 Million Series A Financing

Fortis Therapeutics, an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing. 

“PCF is pleased that the 2017 funding to UCSF for their research on CD46 has been leveraged by Fortis for a meaningful Series A financing,” said Howard R. Soule, PhD, Executive Vice President and Chief Science officer of PCF.